Krystal Biotech

2100 Wharton Street
Suite 701
Pittsburg
Pennsylvania
15203
United States

Tel: 412-586-5830

Show jobs for this employer

About Krystal Biotech

Krystal Biotech is a biopharmaceutical company using gene therapy to develop best in class treatments that provide significant clinical benefit for patients suffering from rare debilitating disorders.
YEAR FOUNDED:
March 2017

42 articles with Krystal Biotech

  • Krystal Biotech , Inc. (Nasdaq:KRYS) today announced that Chief Commercial Officer Jennifer Chien is leaving the company, effective today, to pursue another opportunity. Senior members of Krystal’s commercial team will report directly to Chief Executive Officer Krish Krishnan on an interim basis as the company initiates a search for Ms. Chien’s replacement. “I look forward to working with our commercial leadership team

  • KB301 is designed to deliver a full-length human type 3 collagen transgene via injection - The Phase 1 PEARL-1 clinical study to evaluate KB301 in acne scars and fine wrinkles is currently enrolling PITTSBURGH--( BUSINESS WIRE )-- Krystal Biotech , Inc. (Nasdaq:KRYS) today announced the presentation of positive preclinical data supporting the ongoing development of KB301, an innovative, investigational therapy designed to reverse the decli

  • Krystal Biotech Inc. announced that Krish S. Krishnan, chairman and chief executive officer, will be presenting at the HC Wainwright 22nd Annual Global Investments Conference taking place September 14-16, 2020, as well as participating in a fireside chat at the Morgan Stanley Global Healthcare Conference taking place September 14-18, 2020.

  • KB103 is designed to deliver a full-length human type III collagen transgene via intradermal injection  First in-human study will evaluate the safety and efficacy in acne scars and facial wrinkles Initial data from this study is anticipated in 2021 PITTSBURGH, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq:KRYS), today announced the initiation of the PEARL-1 study, a Phase 1 multi-dose, controlled clinical study of KB301 for the treatment of acne scars and facial

  • Krystal Biotech, Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced that the U.S. Food & Drug Administration (FDA) has granted Orphan Drug Designation to KB407, currently in preclinical development for the treatment of cystic fibrosis (“CF”).

  • Initiated the pivotal GEM-3 clinical study evaluating B-VEC in DEB patients         Today announced enrollment of 1 st patient in Phase 2 clinical study evaluating KB105 in ARCI patients On track to initiate Phase 1 trial of KB301 for an aesthetic indication in 2H 2020         Strong balance sheet with June 30, 2020 cash, cash equivalents and marketable securities of $297 million

  • Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced that Krish S. Krishnan, chairman and chief executive officer, will be participating in a fireside chat at the William Blair BioTech Conference taking place August 4-6, 2020. Details for the presentation are as follows: William Blair BioTech Conf

  • Krystal Biotech, Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced the initiation of GEM-3 study, a multi-center, placebo-controlled, double-blinded, Phase 3 clinical study of beremagene geperpavec (“B-VEC”, previously “KB103”) for the treatment of dystrophic epidermolysis bullosa (DEB) patients.

  • Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.
  • Krystal Biotech , Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced the appointment of Whitney Ijem to the newly created position of Senior Vice President, Strategy and Business Development. Ms. Ijem joins Krystal from Guggenheim Securities, where she served as Managing Director and Senior Biotechnology Analyst covering genetic me

  • Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Krish S. Krishnan, chairman and chief executive officer, will present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast taking place June 9-11, 2020.

  • Krystal Biotech, Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company developing a new class of transformative medicines to treat diseases caused by gene or protein dysfunction, today announced that it has commenced an underwritten public offering of its common stock

  • Krystal Biotech, Inc. (Nasdaq: KRYS) (the “Company”), a gene therapy company developing a new class of transformative medicines to treat diseases caused by gene or protein dysfunction, today announced that it has priced the previously announced underwritten public offering of 2,275,000 shares of its common stock, at a public offering price of $55.00 per share.

  • Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look.
  • KB105 was well tolerated with no adverse events or immune response following redosing Clearly detectable TGM-1 expression in all treated areas following initial and repeat administration. KB105-expressed TGM1 was correctly localized in the epidermis, co-localizing with loricrin, and was functionally active Phenotypic evaluation of KB105 treated areas showed reduced reversion to ichthyotic scaling phenotype Amy Paller, M.D., Professor and Chair of Dermatology at Northwestern University

  • Krystal Biotech reported financial results and key operational progress updates for the first quarter ending March 31, 2020.

  • Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat dermatological diseases, announces financial results for 2019 and an update on its business progress.

  • Biopharma and life sciences strengthen their executive leadership teams and boards with this week's Movers & Shakers.
  • Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced the appointment of Kathryn Romano as chief accounting officer, based in its headquarters in Pittsburgh, PA

  • Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S. Krishnan, chairman and chief executive officer, will present at the Cowen 40th Annual Healthcare Conference in Boston being held March 2-4, 2020 at the Boston Marriott Copley Place.